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Abstract
Objectives Vaccination of healthcare workers (HCWs)
was made a high priority during the phase six pandemic of
the novel inXuenza A H1N1 (pH1N1) virus. We surveyed
adherence to pH1N1 vaccination and the incidence of
pH1N1 infection between vaccinated and unvaccinated
HCWs.
Methods Employees at the S. João Hospital in Porto, Por-
tugal, were oVered pH1N1 vaccinations free of charge.
Pandemrix® was the vaccine administered. As part of the
pandemic plan, employees with inXuenza-like symptoms
(ILS) were called upon to take an RT-PCR H1N1 test. If
the test results were positive, they had to stay oV work for
at least 7 days. Sociodemographic data, vaccination status,
contact with infectious patients, ILS and pH1N1 test results
were documented in a standardised manner.
Results The survey population comprised 5,592 employ-
ees. The vaccination rate was 30.8% (n = 1,720) for pH1N1
and 50.4% (n = 2,819) for the 2009/2010 seasonal trivalent
inactivated inXuenza vaccine (TIV). One mild anaphylactic
reaction occurred after pH1N1 vaccination. Minor local
side eVects occurred more often after pH1N1 vaccination
than after 2009/2010 seasonal TIV (38.0% vs. 12.3%). Pan-
demic H1N1 infection was diagnosed in 97 HCWs (1.7%).
Compared to employees with no regular patient contact,
nurses (2.8%) had the highest risk of pH1N1 infection
(adjusted OR 3.8; 95% CI 1.2–6.8). Vaccination reduced
the pH1N1 infection risk (OR 0.12; 95% CI 0.05–0.29).
Vaccine eVectiveness was 90.4% (95% CI 73.5–97.3%).
Conclusion Vaccination reduced the pH1N1 infection
risk considerably. The pandemic plan to contain the pH1N1
infection was successful. Nurses had the highest risk of
pH1N1 infection and are therefore a target group for vacci-
nation measures.
Keywords Pandemic inXuenza A H1N1 · Healthcare 
workers · Vaccination
Abbreviations
pH1N1 Pandemic inXuenza A H1N1
ILS InXuenza-like symptoms
TIV Trivalent inactivated inXuenza vaccine
HCWs Healthcare workers
OR Odds ratio
RT-PCR Real-time reverse transcriptase–polymerase 
chain reaction
Introduction
In the middle of April 2009, cases of infection with a new
inXuenza virus were detected in Mexico and southern
California (MMWR 2009). This virus was later identiWed
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748 Int Arch Occup Environ Health (2012) 85:747–752as an H1N1 inXuenza virus, with six genes derived from tri-
ple-reassortant North American swine virus lineages and
two genes (encoding neuraminidase and matrix proteins)
derived from Eurasian swine virus lineages (Garten et al.
2009). It rapidly spread to many countries around the
world, prompting the World Health Organization (WHO) to
declare a phase six global inXuenza pandemic on 11 June
2009 (WHO 2009a). At that time, 74 countries had reported
over 27,000 cases of pandemic inXuenza A H1N1 (pH1N1)
and 141 deaths (WHO 2009b). Three months later, the
virus had spread to over 170 countries and was estimated to
have caused 3,486 deaths (WHO 2009c).
The development of an eVective vaccine against the new
strain of the virus and the subsequent implementation of a
large-scale immunisation campaign was considered one of
the most eVective ways to control the pandemic. The immu-
nisation of healthcare workers (HCWs) was given high pri-
ority in order to protect the healthcare infrastructure (WHO
2009d).
In Portugal, a national vaccination plan against the
pH1N1 virus was implemented, using the vaccine Pandem-
rix®, containing 3.75 g of haemagglutinin (General Direc-
torate of Health 2009). It was available from the second
half of October 2009. According to national guidelines, the
vaccine was to be given to priority groups including HCWs
and emergency medical services personnel. The aim of our
study was to analyse the incidence of pH1N1 inXuenza and
the eVectiveness of pH1N1 vaccination in HCWs at a Por-
tuguese tertiary referral teaching hospital.
Methods
The pH1N1 vaccination was oVered to all HCWs working
at S. João Hospital in Porto, Portugal, during the inXuenza
season 2009/2010. Vaccination started on 26 October
2009. No predetermined end date for the vaccination cam-
paign was given. On 10 January 2010, the last HCW was
vaccinated. Participants were asked to remain under obser-
vation for 60 min after vaccination so that any side eVects
could be identiWed. The observation period was limited to
1 h because if severe side eVects, i.e. anaphylactic reac-
tion, occur they will be apparent within the Wrst hour after
vaccination. Furthermore, HCWs were asked to actively
report any side eVects of the vaccination to the vaccination
desk in an informal manner. In addition, HCWs were
either asked directly during their next visit to the OSH-
department or contacted by phone within 3 months of their
pH1N1 vaccination and asked whether any side eVects
occurred. For this interview, a semi-standardised survey
was used containing a list of potential side eVects such as
soreness, redness or swelling at injection site, muscle
aches, or fever.
Seasonal vaccination 2009/2010 commenced on 14 Sep-
tember 2009 using the trivalent inactivated inXuenza vac-
cine (TIV) CHIROFLU® from Novartis Lab. In those
participants with a previous seasonal vaccination, side
eVects of the vaccination were assessed at the time of the
pH1N1 vaccination. Both pH1N1 and seasonal vaccination
were given free of charge to the HCWs and information
regarding the vaccinations was disseminated in a similar
fashion within the hospital.
According to the contingency plan for pH1N1 control,
HCWs with inXuenza-like symptoms (ILS) were attended
to by a specialised physician at the pH1N1 task force unit
created in the Emergency Department. The task force
examined HCWs with ILS and oVered antiviral treatment.
This treatment was only available in the hospital. A naso-
pharyngeal or oropharyngeal tissue swab was taken from
each HCW with ILS for the detection of the pH1N1 virus,
using the real-time reverse transcriptase–polymerase chain
reaction (RT-PCR) method.
All HCWs were monitored by the Occupational Health
Division and requested to stay at home until the test results
were known. The HCWs were allowed to return to their
usual workplace if the result of the RT-PCR was negative
and the symptoms had improved. However, if the RT-PCR
was positive, the HCWs had to stay at home for a period of
at least 7 days. This sick leave did not result in any loss of
income or beneWts regardless of the RT-PCR result. The
analysis is restricted to ILS or pH1N1 infections that
occurred after pH1N1 vaccination was available. Before 26
October, only eleven cases of ILS and two cases of pH1N1
infection were registered. Before the swab was taken, symp-
toms were recorded and HCWs were asked whether they
had had contact with patients or other persons with ILS.
The contingency plan for pH1N1 control not only rec-
ommended vaccination, antiviral treatment and social dis-
tancing but also emphasised disinfection, hand-washing
and use of masks in order to prevent transmission. How-
ever, these latter aspects were not part of this analysis.
Data analysis was performed with SPSS, version 13.
Adjusted odds ratio (OR) and 95% conWdence interval (CI)
for putative risk factors for ILS or pH1N1 infection were
calculated. Pearson’s Chi-square test was employed for cat-
egorical data using  < 0.05 as the signiWcance level. The
number of prevented cases of pH1N1 inXuenza was calcu-
lated by subtracting the observed cases in vaccinated
HCWs from the expected cases had the HCWs not been
vaccinated. Vaccine eVectiveness (VE) was estimated using
the following formula: VE = (PPV¡PCV)/(PPV(1¡PCV))
£ 100%, where PPV is the proportion vaccinated in the
cohort and PCV the proportion of vaccinated cases
(Farrington 1993). For this calculation, an HCW was con-
sidered vaccinated when the onset of symptoms started
later than 1 week after the vaccination. The ethical integrity123
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eral Directorate of Health 2009) and HCWs gave their
informed consent to an anonymous analysis of their data.
Results
The study sample comprises 5,592 HCWs with and without
regular patient contact (Fig. 1). In total, 1,720 HCWs were
vaccinated against pH1N1 (30.8%), including 52 pregnant
HCWs (Table 1). 50.4% of the study population received
seasonal TIV for the season 2009/2010. Nurses had the
highest vaccination rate (62.5%) for seasonal TIV but only
the second highest rate (30.3% compared to 43.9% in phy-
sicians) for pH1N1 vaccination (Table 2).
After pH1N1 vaccination, one woman experienced an
anaphylactic reaction with dizziness and hypotension last-
ing a few minutes. No further complications were observed
during the Wrst hour after vaccination and no side eVects
warranting medical attention were reported. After pH1N1
vaccination, myalgia (6.9%), mild local reaction (38.0%)
and strong local reaction (1.9%) were reported to the vacci-
nation desk (Table 3). No complications occurred in the 52
pregnant participants. Assessed retrospectively, 83.4%
reported no side eVects from the seasonal TIV, 12.3% mild
local reactions and 2.9% myalgia. Strong local reactions
(0.7%), fatigue (0.3%), fever (0.3%), headaches (0.1%) and
lymph node swelling (0.1%) were seldom. Therefore, more
side eVects were reported after pH1N1 vaccination than
after the 2009/2010 seasonal TIV.
Between 26 October 2009 and 2 March 2010, 245
HCWs with ILS (4.4%) were referred to the pH1N1 task
force in the Emergency Department (Table 1). Of these,
pH1N1 virus infection was conWrmed in 97 cases (39.6%).




·30 years 1,471 26.3
31–40 years 1,724 30.8
41–50 years 1,236 22.1





Auxiliary staV 1,273 22.8
Administration or others 944 16.9
Vaccination
pH1N1 1,720 30.8
Seasonal 09/10 TIV 2,819 50.4
Seasonal 08/09 TIV 2,127 38.0
Seasonal inXuenza
No vaccination 2,172 38.8
TIV in 2008/2009 601 10.7
TIV in 2009/2010 1,293 23.1
TIV in both seasons 1,526 27.3
InXuenza-like symptoms (ILS) 245 4.4
ConWrmed pH1N1 infection 97 1.7
Table 2 Seasonal TIV and 2009 pH1N1 vaccination rates by
profession
Profession TIV pH1N1-vacc.
N % N %
Nurses 1,238 62.5 601 30.3
Physicians 650 46.7 611 43.9
Auxiliary staV 602 47.3 252 19.8
Administration or others 329 34.9 256 27.1
Fig. 1 Flow chart of the study 
population. Pearson’s Chi-
square test for pH1N1 infection 
yes or no depending on pH1N1 
vaccination in the group with 
seasonal TIV (p < 0.0001) and 
























750 Int Arch Occup Environ Health (2012) 85:747–752Indeterminate results were observed in two out of 245
examinations (0.8%). After performing a second test, one
case remained indeterminate.
The peak in ILS and pH1N1 infection in HCWs came in
the 49th week of 2009. ILS occurred less often in pH1N1-
vaccinated HCWs (OR 0.7; 95% CI 0.51–0.95), while the
seasonal TIV showed no protective eVect against ILS (OR
1.0; 95% CI 0.79–1.36). Gender was not associated with
ILS (Table 4). Younger workers were more likely to pres-
ent with ILS (OR for ·30 years: 2.7; 95% CI 1.69–4.42).
After adjusting for vaccination, nurses (OR 2.5; 95% CI
1.53–4.09) and physicians (OR 2.0; 95% CI 1.21–3.41) had
a higher risk of developing ILS than administrators.
Out of the 97 pH1N1 infections, 91 (94%) occurred in
non-vaccinated HCWs and two (2%) in HCWs vaccinated
less than a week before the onset of symptoms. Overall,
pH1N1 incidence was 1.7% of all HCWs, aVecting 0.3% of
those vaccinated and 2.4% of those not vaccinated
(Table 5). The seasonal TIV did not protect against pH1N1
infection (OR 1.5; 95% CI 0.98–2.27) and neither did con-
secutive seasonal TIV in 2008 and 2009 (Table 1) (data not
shown). Young HCWs were more often aVected (OR for
·30 years: 6.6; 95% CI 2.57–16.8, Table 5). Nurses had an
increased risk of pH1N1 infection (OR 2.7; 95% CI 1.11–
6.37), while physicians had an increased but not statisti-
cally signiWcant risk (OR 1.8; 95% CI 0.71–4.62). A total
of 41 pH1N1 infections would have been expected in the
vaccinated HCWs if they had not been vaccinated. The
number of prevented cases is therefore 35 (41 expected
minus six observed cases). The number to vaccinate in
order to prevent one case of pH1N1 inXuenza was 49 in this
particular cohort. Vaccine eVectiveness (VE) was 90.4%
(95% CI 73.5–97.3%).
Sixty-two (64%) of the pH1N1 infected HCWs had had
known contact with a pH1N1 infected individual and
another 17 HCWs (17.5%) had had contact with symptom-
atic individuals. Fifty out of 79 potential sources of infec-
tion (63%) were patients in the hospital. The most frequent
symptoms associated with pH1N1 infection were muscle or
joint pain (85%), coughing (78%), fever (77%), headache
(61%) and sore throat (40%). The disease was benign in its
evolution in all cases.
Discussion
To our knowledge, this is the Wrst study to analyse the inci-
dence of pH1N1 infection and vaccine eVectiveness in
HCWs in the 2009/2010 season. According to our data,
nurses were the most aVected group. Most of the known
infectious contacts were with patients. The vaccination rate
was 30.8, and 94% of the pH1N1 infections were observed
in the unvaccinated HCWs. Vaccination reduced the attack
rate of pH1N1 from 2.4 to 0.3%. Vaccination may have
prevented 35 pH1N1 infections in this particular cohort and
pandemic season. Calculated vaccine eVectiveness was
90.4% and therefore high.
The pandemic plan at S. João Hospital ensured that no
HCWs who took sick leave due to ILS suVered any loss of
Table 3 Side eVects of seasonal vaccination 09/10 in those 1,144
HCWs who obtained pH1N1 vaccination and side eVects of pH1N1
vaccination
* Multiple responses were possible
Side eVects* 2009/2010 seasonal TIV pH1N1
N % N %
No side eVects 954 83.4 994 57.8
Fatigue 3 0.3 10 0.6
Headache 1 0.1 3 0.2
Temperature > 38°C 3 0.3 9 0.5
Myalgia 33 2.9 119 6.9
Lymph node swelling 1 0.1 –
Mild local reaction 141 12.3 654 38.0
Strong local reaction 8 0.7 32 1.9
Total 1,144 100.0 1,720 100.0
Table 4 Logistic regression for putative risk factors of inXuenza-like
symptoms (ILS)
Variable ILS OR 95% CI
Neg. Pos.
N (%) N (%)
pH1N1 vaccination
No 3,690 (95.3) 182 (4.7) 1 –
Yes 1,657 (96.3) 63 (3.7) 0.7 0.51–0.95
Seasonal TIV 09/10
No 2,658 (95.9) 115 (4.1) 1 –
Yes 2,689 (95.4) 130 (4.6) 1.0 0.79–1.36
Gender
Female 3,856 (95.4) 186 (4.6) 1 –
Male 1,491 (96.2) 59 (3.8) 0.9 0.64–1.18
Age (years)
·30 1,379 (93.7) 92 (6.3) 2.7 1.69–4.42
31–40 1,638 (95.0) 86 (5.0) 2.3 1.42–3.72
41–50 1,191 (96.4) 45 (3.6) 1.8 1.01–3.03
>50 1,139 (98.1) 22 (1.9) 1 –
Profession
Nurses 1,854 (93.5) 128 (6.5) 2.5 1.53–4.09
Physicians 1,330 (95.5) 63 (4.5) 2.0 1.21–3.41
Auxiliary staV 1,239 (97.3) 34 (2.7) 1.1 0.63–1.95
Administration 
or others
924 (97.9) 20 (2.1) 1 –123
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regardless of whether it was caused by pH1N1 infection or
not. Furthermore, antiviral treatment was only oVered to
those who reported to the Emergency Department. These
two circumstances increased the likelihood of reporting
ILS. Therefore, this could well have neutralised any poten-
tial reluctance to report ILS to the pandemic task force.
However, asymptomatic infections could not be detected by
testing HCWs with ILS only and infections with mild
symptoms are likely to have been underreported. This limi-
tation renders it likely that the incidence of pH1N1 infec-
tion was underestimated in our cohort. However,
underreporting was most likely non-diVerential and there-
fore did not inXuence the estimate of vaccine eVectiveness.
In a previous German study, vaccine eVectiveness was esti-
mated to be 96.8% in the general population (Wichmann
et al. 2010). Therefore, the vaccine eVectiveness we found
in HCWs (90.4%) was slightly lower. For the United King-
dom, a lower vaccine eVectiveness of 71% was reported
(Hardelid et al. 2011). Vaccine eVectiveness increased to
72% if vaccination was assumed to be eVective 2 weeks
after injection instead of one, as we assumed. In a European
multicentre study, vaccine eVectiveness was 78.4% in per-
sons <65 years (Valenciano et al. 2011). Therefore, our
observation is well within the range of vaccine eVective-
ness found in other populations.
The vaccination rate against the pH1N1 virus (30.8%)
was signiWcantly lower than for the seasonal TIV in the
same year (50.4%). Similar ratios were also described by
other authors, with pH1N1 vaccination levels varying,
depending on country and institution, between 15 and 37%
(Wicker et al. 2010; Sullivan et al. 2010). The main cause
of pandemic vaccine refusal was concern about its safety
and the belief that it was not needed (Rachiotis et al. 2010;
SteelFisher et al. 2010; Ofri 2009). Our data suggest that
the pH1N1 vaccination was safe and eVective. Side eVects
were more frequent after pH1N1 vaccination than after sea-
sonal TIV. However, they were mostly minor local reac-
tions. As a limitation of the study, it should be noted that
underreporting of side eVects of seasonal TIV is possible if
side eVects of seasonal TIV discouraged HCWs from
accepting pH1N1 vaccination. Underreporting of side
eVects caused by the pH1N1 vaccination is not likely
because in addition to active reporting of side eVects to the
vaccination desk a survey on side eVects was performed
with all HCWs who received the vaccination. The fre-
quency of side eVects we observed was similar to that
described in an Italian HCWs study, which reported pain at
the injection site (43.4%) as the most frequent adverse reac-
tion (Amodio et al. 2011). As increased knowledge and
awareness could well have an improved impact on adher-
ence to vaccination schemata, our data might help to con-
vince HCWs to take part in vaccination campaigns for the
coming inXuenza seasons (Hofmann et al. 2006).
Seasonal inXuenza vaccination was not eVective against
pH1N1 infection. This corroborates the Wndings of JeVeries
et al. (2011) from New Zealand. The authors conclude that
2009 seasonal inXuenza vaccination had no protective
eVect against pH1N1 infection amongst HCWs.
The major limitation of our study is that only partici-
pants with ILS were tested for pH1N1 infection. There
might have been underreporting of ILS, and a certain num-
ber of pH1N1 infections might have been asymptomatic
and therefore remained unnoticed. However, surveys on the
incidence of pH1N1 infections describe infection rates very
similar to our Wndings in HCWs who were not vaccinated
(Reed et al. 2009, 2011; Santos et al. 2010; Brammer et al.
2011). This corroborates the infection rates we found and
renders serious underreporting unlikely. Furthermore, the
sensitivity and speciWcity of the RT-PCR for pH1N1 are
suitable for diagnostic use but they are not perfect (Ellis
et al. 2009). Tests for antibodies after the infection or ILS
were not performed in order to conWrm the pH1N1
infection. This might have resulted in false positive or
false negative results. However, this should have led to
non-diVerential misclassiWcation and dilution of the pre-
ventive eVect of pH1N1 vaccination. Therefore, the vaccine
Table 5 Logistic regression for putative risk factors for pH1N1 infec-
tion
Variables pH1N1 OR 95% CI
Neg. Pos.
N (%) N (%)
pH1N1 vaccination
No 3,781 (97.6) 91 (2.4) 1 –
Yes 1,714 (99.7) 6 (0.3) 0.12 0.05–0.29
Seasonal TIV 09/10
No 2,732 (98.5) 41 (1.5) 1 –
Yes 2,763 (98.0) 56 (2.0) 1.5 0.98–2.27
Gender
Female 3,972 (98.3) 70 (1.7) 1 –
Male 1,523 (98.3) 27 (1.7) 1.1 0.72–1.82
Age (years)
·30 1,421 (96.6) 50 (3.4) 6.6 2.57–16.8
31–40 1,692 (98.1) 32 (1.9) 3.8 1.47–9.95
41–50 1,226 (99.2) 10 (0.8) 1.7 0.59–5.09
>50 1,156 (99.6) 5 (0.4) 1 –
Profession
Nurses 1,926 (97.2) 56 (2.8) 2.7 1.11–6.37
Physicians 1,374 (98.6) 19 (1.4) 1.8 0.71–4.62
Auxiliary staV 1,257 (98.7) 16 (1.3) 1.4 0.55–3.65
Administration 
or others
938 (99.4) 6 (0.6) 1 –123
752 Int Arch Occup Environ Health (2012) 85:747–752eVectiveness observed in our study is unlikely to be overes-
timated. Side eVects of the pH1N1 vaccination were
directly observed during the Wrst hour after vaccination. It
should be noted that information on other side eVects was
based on informal reports to the vaccination desk and a
semi-standardised survey either in person or over the
phone. Therefore, underestimation of the incidence of side
eVects after pH1N1 vaccination is possible but not likely to
introduce a signiWcant bias.
Conclusions
Vaccine eVectiveness seemed to be high in HCWs during
the inXuenza A H1N1 season 2009/2010. The pandemic
plan to contain pandemic inXuenza A H1N1, with its vari-
ous methods, was successful. The use of vaccines signiW-
cantly reduced the expected number of illnesses. Nurses
had the highest risk of pH1N1 infection and are therefore a
target group for vaccination measures.
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